2 results
Approved WMORecruiting
To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)
Approved WMORecruiting
Main study:Primary:Efficacy:- To assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versusplacebo in STEMI subjects in the pre-hospital setting.Safety:- To assess bleeding events (…